Open AccessStudy on myelin injury of AD mice treated with Shenzhiling oral liquid in the PI3K/Akt–mTOR pathway
Author(s) -
Yahan Wang,
Fang Chen,
Pengwen Wang,
Lulu Mana,
Ning Sheng,
Songming Huang
Publication year - 2020
Publication title -
international journal of immunopathology and pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.724
H-Index - 53
eISSN - 2058-7384
pISSN - 0394-6320
DOI - 10.1177/2058738420923907
Subject(s) - pi3k/akt/mtor pathway , protein kinase b , morris water navigation task , western blot , myelin basic protein , immunohistochemistry , medicine , chemistry , pharmacology , endocrinology , myelin , hippocampus , phosphorylation , signal transduction , biochemistry , central nervous system , gene
Shenzhiling oral liquid (SZL) is a Traditional Chinese Medicine (TCM) compound to be approved by the China Food and Drug Administration (CFDA) (Z20120010) for the treatment of mild-to-moderate Alzheimer’s disease (AD). However, its mechanism in early AD is not clear. We studied its mechanism in protecting myelin. Three-month-old APPswe/PS1dE9double transgenic mice were used as AD model and wild-type C57BL/6 mice were used as control. After 3-month intervention, the Morris water maze was used to detect behavioural changes. Myelin mTOR pathway (PI3K, p-PI3K, Akt, p-Akt, mTOR, p-mTOR), myelin basic protein (MBP) and postsynaptic density protein 95 (PSD95) were detected by immunohistochemistry and western blot and reverse transcriptase polymerase chain reaction (RT-PCR). After 3 months of SZL treatment, compared with the model group (M), SZL medium-dose (SM) and SZL low-dose groups (SL) exhibited increased staying and crossing results in Morris water maze ( P 0.05), mTOR mRNA expression in all the drug-treated groups increased significantly ( P < 0.01) and MBP mRNA and PSD95 mRNA expression in D and SH increased ( P < 0.05). SZL oral liquid could play a role in myelin protection in early AD.